We are making early stage cancer 100,000x easier to find using extracellular vesicles found in blood, specific to their parent cells.
Location: United States, Massachusetts, Natick
Total raised: $41M
Investors 5
| Date | Name | Website |
| 13.02.2021 | Broadway A... | broadway-a... |
| - | iSelect Fu... | iselectfun... |
| 05.05.2023 | BrightEdge | brightedge... |
| 26.03.2021 | The Perkin... | theperkins... |
| - | BrightEdge | acsbrighte... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.04.2023 | Series A | $41M | - |
Mentions in press and media 4
| Date | Title | Description |
| 23.05.2024 | Landmark Study from Mercy BioAnalytics and University College London Demonstrates Significant Improvement Over CA125 and Ultrasound for Ovarian Cancer Screening | Mercy Halo™ Test demonstrates 82% sensitivity and 98% specificity in a retrospective blinded analysis of prospectively collected samples from 1300 asymptomatic women WALTHAM, Mass., May 23, 2024 /PRNewswire/ -- Mercy BioAnalytics, Inc., a p... |
| 06.04.2023 | Extracellular Vesicle-Based Liquid Biopsy Company Mercy BioAnalytics Secures $41 Million | Mercy BioAnalytics – a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer – announced it has closed a $41 million Series A financing round. This oversubscribed financing was led by Novalis LifeSciences ... |
| 03.04.2023 | Mercy BioAnalytics Raises $41M in Series A Funding | Mercy BioAnalytics, a Natick, MA-based company focused on advancing extracellular vesicle-based liquid biopsies for the early detection of cancer, raised $41M in Series A funding. The round was led by Novalis LifeSciences, with participatio... |
| - | Mercy BioAnalytics | “We are making early stage cancer 100,000x easier to find using extracellular vesicles found in blood, specific to their parent cells.” |